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Summary We report for the first time the frequency distributions of HLA-DRB1 and -DQB1 genes in 55 patients with testicular germ cell
carcinoma (TGC) using the modified PCR-RFLP method and compare the results with those for 1216 healthyJapanese control subjects. The
modified PCR-RFLP method produced accurate, reproducible cleavage patterns that are easily discriminated. HLA-DRB1*0410 was the
susceptibility allele (RR = 3.26, P= 0.006) and DQB1*0602 appears to be a candidate protective allele (RR = 0.26, P = 0.02) for TGC in the
Japanese. None of the HLA-DRB1 and -DQB1 alleles showed a specific tendency for histological type or clinical stage of the tumours.
Previous studies based on serotyping methods failed to show these allelic associations. High-resolution genotyping is essential because the
peptide-binding domain of MHC class 11 molecules is determined more precisely by their genotypes than by their serotypes. In addition,
inherent technical difficulties and typing errors of up to 25% make serotyping inefficient. Our results suggest that high-resolution genotyping
is a useful genetic marker to determine risk for TGC.
Keywords: testicular germ cell carcinoma; MHC class 11 genotyping; modified PCR-RFLP; allele frequency
Testicular germ cell carcinoma (TGC), although relatively rare in
the male population in general, is the most common malignancy in
men between the ages of 15 and 35 years. Strong evidence for the
involvement of genetic factors has been reported in TGC develop-
ment. The incidence ofTGC in first degree relatives is 2.2%, and in
unrelated individuals 0.4%. For an individual who has a father or
brother with TGC, the relative risk ofdeveloping TGC is increased
sixfold compared with men in the general population. The concor-
dance of tumour histology is high in twins and low in father-son
pairs (Tolerud et al, 1985). Moreover, the incidence ofTGC is rela-
tively high among white American men in comparison with black
American or Oriental men living in the same geographical areas
(Senturia, 1987). Finally, as a pluripotential, polymorphic and
commonly heterogeneous cancer, TGC is markedly affected by the
host environment, e.g. when a murine embryonal carcinoma cell is
placed in a mouse blastocyte, it may differentiate in an orderly
fashion and participate in the creation of a normal mouse (Richie,
1992). All this evidence suggests that HLA association could be
one ofthe genetic factors in the development ofTGC.
Previous studies (DeWolfet al, 1979; Pollack et al, 1982; Oliver
et al, 1986; Aiginger et al, 1987; Kratzig et al, 1989) on the associ-
ation of HLA antigens with TGC have shown no association with
the HLA-A and HLA-C regions, and inconsistent association with
the HLA-B region. Despite the inherent technical limitations of
conventional methods used for HLA-DR typing, such as cytotoxi-
city, previous studies have claimed a consistent association of
TGC with HLA-DR antigens. Some of these studies have
suggested the need for genotyping (Oliver et al, 1986; Yoshimura
Received 15January 1997
Revised 15April 1997
Accepted 1 May 1997
Correspondence to: Osamu Yoshida, Department of Urology, Faculty of
Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto
606-01, Japan
et al, 1993). Our study is the first high-resolution HLA-DRB1 and
DQB1 genotyping ofpatients with TGC.
Reports published up to 1982 did not include HLA-DR. Later
studies included the DR region, but the number of antigens deter-
mined was limited (Pollack et al, 1982). This means that, up to
now, there has been no complete HLA-DRB1 typing, even by
serotyping. The purpose of our molecular epidemiological study
was to identify high-risk individuals, thereby allowing for their
close surveillance and the early detection of these potentially
curable tumours.
MATERIALS AND METHODS
Patients and controls
Fifty-five Japanese patients with TGC confirmed histopathologi-
cally were obtained for study from the 1990-96 tumour registries
at Kyoto University Hospital and its affiliated hospitals without
any selection criteria. The histological diagnosis and clinical stage
were based, respectively, on the modified WHO classification
system (Mostofi and Sobin, 1977) and the tumour-nodes-
metastasis staging systems (UICC, 1989). The clinicopathological
profiles of the patients are given in Table 1. As controls, we used
the genetic frequencies ofHLA-DRB1 and -DQB1 in 1216healthy
Japanese subjects reported at the 11th Japanese HLA Genotyping
Workshop held by the Japanese Society for Histocompatibility and
Immunogenetics in 1994 (Akaza et al, 1994).
DNA extraction and PCR-RFLP
High molecular weight genomic DNA was extracted from the
patients' peripheral blood lymphocytes afterproteinase Kdigestion
by the standard phenol-chloroform method (Perucho et al, 1981).
The modified PCR-RFLP method for HLA-DRB1 genotyping
described by Ota et al (1992) and that for HLA-DQB1 describedby
Nomura et al (1991) were used. Briefly, the polymorphic exon 2
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Table 1. Clinicopathological profiles of the TGC patients
No. of patients 55
Age 3-64 (35± 11)a
Histological type
Pure seminoma 31
NSGCTb 24
TNM stage
Low stagec 34
High staged 21
aMedian ± SD. bNon-seminomatous germ cell tumours (with or without a
seminomatous component). cNO, Ni, N2A. dN2B, N3, M+.
domains ofthe DRBI and DQBI genes were amplified. Each PCR
was amplified in a 25-jl mixture of approximately 100 ng of
genomic DNA, 25 pmol of each primer, 500 gM each of dATP,
dGTP, dCTP, and dTTP and 1.25 U ofAmpliTaq DNA polymerase
(Roche Molecular Systems, Branchburg, NJ, USA). This mixture
was subjected to 35 PCR cycles, each of which was divided into
periods of94°C for 30 s, 55°C for 40 s, and 72°C for 60 s, with a
final 3-min extension at 72°C. For some primers, the annealing
temperature was increased to 62'C on the basis of preliminary
PCR results in order to eliminate non-allelic bands. Loading buffer
was mixed with 4 ,l ofthe PCR products and electrophoresed in a
2% horizontal agarose gel in a minigel apparatus (Mupid-2,
Cosmo Bio Co., Tokyo, Japan). Five microlitres ofthe PCR prod-
ucts was digested at the appropriate temperature for 1 h with 3-5
units of the following restriction enzymes: Avall and PstI for
DRB1-DR1; FokI, Cfrl3I and HphI for DRB1-DR2; SaclI, AvaIl,
Hinfl, HaeII, HphI and MnLI for DRB1-DR4; AvaII, FokI, KpnI,
HaeII, Cfrl3I, SfaNI, SacIl, BsaJI, Apal and HphI for DRB1-
DR3568; FokI, Apal, HaeII, SfaNI, BssHII and HphI for DQB1-
DQ1; and FokI, BgII, Sacd, Acyl and HpaII for DQB1-DQ2, 3, 4,
together with the corresponding buffer (1-2 ,ul), at a final volume
of 10 gl in distilled water. The digested PCR products were
electrophoresed through a vertical polyacrylamide gel in a micro-
gel apparatus then stained with ethidium bromide (0.5 mg ml-').
Data analysis
Depending on the sample size, Fisher's exact probability test orthe
chi-square test was used to analyse all the 2 x 2 tables. P < 0.05
was considered statistically significant. Relative risk (RR) was
calculated as (a x d)/(b x c), where a, b, c and d are, respectively,
the numbers ofmarker (+) patients, marker (-) patients, marker (+)
controls and marker (-) controls. An RR value less than than 0.5
was assigned as relatively low risk, and an RR value more than 2
was assigned as relatively high risk. We performed significance
tests only for those alleles with relatively low risk or relatively
high risk. P-values were corrected by the number of comparisons
made in the overall study. The 5-value was estimated according to
Thompson (1981). Values of the preventive fractions (PFc, PF)
and aetiological fractions (EFc, EF) were estimated according to
Green (1982).
RESULTS
The modified PCR-RFLP method produced accurate, repro-
ducible, and easily discriminative cleavage patterns of high-
resolution HLA-DRB1 and DQB1 genotyping (Fig. 1). The distri-
bution of the HLA-DRB1 and DQB1 genotypes together with the
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Figure 1. A representative 10% polyacrylamide/ethidium bromide-stained
gel showing cleavage patterns of polymorphic restriction fragments obtained
by the modified PCR-RFLP method from two patients with the protective
allele, DQB1*0602. At completion ofdigestion, a coding system depending
on the availability ofdigested (1), non-digested (0) and both digested and
non-digested (2) bands was used. Left: The cleavage pattern of the
protective allele, DQB1*0602, of patient A. Right: Its combination with the
DQB1*0503 of patient B. DOB1*0503determination was clarified by further
digestion with Hph
RR ratios for 55 patients with TGC vs those for 1216 healthy
Japanese control subjects are shown in Table 2. The HLA class II
allele,DRBJ*0410, asubtype ofDR4, was significantly associated
with susceptibility in Japanese TGC patients compared with the
healthy Japanese control subjects (5.45% vs 1.79) (RR = 3.26, P =
0.006). The aetiological fraction of exposed individuals (EFc)
carrying DRBI*0410 was 0.69, which means hypothetically that,
if the presence of this allele per se is a susceptibility factor for
TGC development in Japanese male patients with TGC who carry
the DRBI*0410 allele, 69% ofthe cases developed because ofthe
presence of this susceptibility gene. The aetiological fraction of
the total population (EF) was 0.08, which means that 8% of
Japanese male patients with TGC developed testicular cancer
because ofthe presence ofthis susceptibility gene.
The association ofthe low relative risk values ofthe DRBI*0406,
*1401 and 1501 and DQBI*0502 alleles in patients with TGC was
not significant when compared with the values for the healthy
Japanese control subjects. DQBI*0602 appears to be a candidate
protective allele for patients with TGC compared with the healthy
subjects (1.81% vs 6.22%) (RR = 0.26, P = 0.02). Because in our
study this association was not significant after correction for the
number ofcomparisons made, further studies are needed for confir-
mation. If the preventive fraction of individuals carrying
DQBI*0602 (PFc) was0.74, which means thatifHLA-DQBI*0602
per se prevents TGC, then it would have prevented 74% ofthe cases
that would otherwise have occurred among the DQBI*0602-posi-
tive individuals. The preventive fraction ofthe total population (PF)
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Table 2. Distribution of HLA-DRB1 and DQB1 alleles in 55 patients with TGC and 1216 healthy controls, and distribution of the histological type and TNM
stage vs HLA-DRB1 and DQB1 alleles
Alleles TGC Controlsa RR P Seminoma NSGCT TNM (low) TNM (high)
DRB1*0101
*0301
*0302
*0401
*0403
*0404
*0405
*0406
*0407
*0408
*0410
*0700
*0802
*0803
*0804
*0901
*1001
*1101
*1102
*1103
*1201
*1202
*1301
*1302
*1304
*1401
*1402
*1403
*1405
*1406
*1407
*1501
*1502
*1601
*1602
DQB1*0201
*0301
*0302
*0303
*0401
*0402
*0501
*0502
*0503
*0504
*0601
*0602
*0604-6
5
0
0
0
4
0
17
1
0
0
6
1
4
10
1
14
0
3
1
2
5
3
0
8
0
1
2
0
2
1
0
4
13
0
2
0
12
7
19
20
6
5
1
4
0
24
2
10
141
2
1
15
51
11
322
74
17
3
44
6
102
202
5
342
17
63
1
89
43
14
166
1
82
5
46
54
42
3
173
246
1
25
9
282
227
361
317
97
159
61
99
1
441
151
171
0.76
1.79
1.24
0.28
3.26
0.85
1.12
0.87
1.05
0.99
1.57
1.07
0.25
0.81
0.47
1.22
0.92
0.63
1.25
1.62
1.41
0.66
0.35
0.88
1.36
0.26
1.35
0.15
0.006
0.11
0.09
0.210
0.020
2
4
10
0
4
1
7
1
8
2
1
1
2
3
2
0
1
2
1
2
6
6
6
10
13
4
2
1
3
13
1
3
3
0
7
2
0
3
3
0
6
1
0
1
3
0
6
1
1
0
0
2
7
6
1
9
7
2
3
0
1
11
1
7
3
4
12
0
4
1
2
5
0
9
2
1
1
3
2
5
0
0
2
1
2
8
7
5
12
15
3
3
1
3
12
1
6
2
0
5
1
2
0
2
5
1
5
1
0
1
2
1
3
2
0
0
2
5
5
2
7
5
3
2
0
1
12
1
4
RR, relative risk; NSGCT, non-seminomatous germ cell tumours (with or without a seminomatous component).aAkaza et al (1994).
was 0.03. Correspondingly, DQBI*0602 would have prevented 3%
ofthe cases that would have developed among Japanese male indi-
viduals ifthis allele had nothad apreventive effect.
Haplotype frequency and linkage disequilibrium of low-
frequency alleles, DRBI*150J;DQBI *0602, in control subjects
and patients were 6.16/3.64 and 1.21/2.95 respectively. The
DRBI*J5SO and DQBI*0602 haplotypes were less frequent and
linkage disequilibrium was stronger in patients with TGC than in
healthy control subjects. Haplotype frequency and linkage disequi-
librium of high-frequency alleles, DRBI*0410;DQBI *0402 in
control subjects and patients were 1.54/7.27 and 4.05/22.45
respectively. The DRBI*0410 and DQBI*0402 haplotypes were
more frequent and linkage disequilibrium was much stronger in
patients with TGC than in healthy control subjects.
When more than one allele shows an association with a partic-
ular disease, the appropriate measure for determining which allele
has the strongest association with the disease is the 6-value. The 6-
value for the susceptibility allele DRBI*0410 was 4.63, and forthe
relatively protective allele DQBI*0602 was 0.85. The preventive
fractions (PFc, PF) demonstrate that, among individuals who carry
DQBI*0602, this allele is highly protective. In the general male
population, expression ofthe DRBI*0410 allele causes the highest
susceptibility, and this allele is the allele most significantly associ-
ated with TGC tumours.
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The associations of DRBI*0403 and DQBI*0302 with semi-
noma and low-stage tumours were not significant (P > 0.05).
There was no specific association between the other DRBI and
DQBI alleles and histological type or clinical stage ofthe tumours.
The clinicopathological data collected in our study were taken
from first admission information, which may be the reason for the
discrepancy. In fact, the status of both TGC patients who carried
the protective allele DQBI*0602, one with initial stage pT2NOMO
seminoma and one with stage pT3N4M1 embryonal cell carci-
noma, showed no evidence ofdisease after 5 years of survival.
DISCUSSION
HLA-DRBI*0410 showed a highly significant association with
susceptibility to TGC, and DQBI*0602 appeared to protect against
TGC development. The validity of the latter statement, however,
needs to be confirmed. Previous studies (DeWolf et al, 1979;
Pollack et al, 1982; Oliver et al, 1986; Aiginger et al, 1987; Kratzig
et al, 1989) that used conventional methods, such as microcyto-
toxicity, failed to show this allelic association. High-resolution
genotyping is essential because the polymorphism of the peptide-
binding domain ofMHC class II molecules is more precisely deter-
mined by genotypes than by serotypes. TheHLA-DRBI and -DQBI
genes are extremely polymorphic, and the amino acids they encode
are located in regions that line the sides and floor of the peptide-
binding groove, which is related to immune responsiveness as well
as to the ability to bind antigenic peptide and to be recognized by
CD4 T-cell receptors (Rukstalis et al, 1989; Nomura et al, 1991;
Ota et al, 1992; Ayala, 1995; Futami et al, 1995).
Despite the difficulties inherent in conventional HLA-typing
methods, on the basis of NIH microcytotoxicity findings DeWolf
et al (1979) reported that HLA-A, and -B antigens were not associ-
ated with TGC and that Drw7 was more frequent in teratocarci-
noma (RR = 8.32). Pollack et al (1982), who typed 145 white
American males with TGC tumours, found no association with
HLA-C antigens, but reported a high frequency of DR5 in pure
seminoma cases. Aiginger et al (1987), who typed 66 patients with
TGC, have reported a high frequency of DR5 antigen with metas-
tasis. Oliver et al (1986) have reported increased DR5 antigen and
decreased DR3 antigen frequencies in seminoma. In 1989, Kratzig
et al pooled all the previous data with their results on HLA typing
for TGC and reported a significantly increased frequency of
DR5 in seminoma and some association of HLA-B13 with non-
seminomatous germ cell tumours. These previously reported find-
ings are adequate for MHC class I typing but not for class II
typing. In fact, none of the reports up to 1982 included HLA-DR
and, although later studies included the DR region, the number of
antigens determined was limited (Pollack et al, 1982). With regard
to the serotype frequencies found in our study, DR5 was slightly
more frequent in TGC patients than in the control subjects (12.72
vs 8.10) and showed a greater tendency for semonima. DR3 and
DR7 are very infrequent in the Japanese population (0.12% and
0.25% respectively). The inconsistency in the reports on the asso-
ciation of some of HLA-B antigens with TGC tumours may stem
from the strong linkage between the HLA-B and HLA-DRBI
regions. The weaker antigenicity of HLA-A than HLA-B reported
in organ transplants, despite the antigens' structural similarities, is
attributed mainly to the weak association ofHLA-A with HLA-DR,
whereas HLA-B has a strong association with HLA-DR (Tiercy et
al, 1991;Ichikawaetal, 1993).
The strong influence of MHC complex genes on the develop-
ment of diseases with a mainly autoimmune background has been
reported. The demonstration ofthe major role ofmouse MHC (H-2)
in determining resistance to the development of murine leukaemia
led to a number of studies. Two tumour types, Hodgkin's disease
and nasopharyngeal carcinoma, have consistently been reported to
be significantly associated with HLA antigens in both unrelated
and familial studies (DeWolf et al, 1979; Oliver et al, 1986;
Senturia, 1987).
Theoretically, cancer may arise under conditions of genetic or
acquired reduced immune capacity. In patients undergoing organ
transplants, a significant overall two- to five-fold increased risk of
TGC tumours has been reported. This confirms that an impaired
immune system allows carcinogenic factors to act. The worldwide
epidemic of acquired immunodeficiency syndrome (AIDS)
provides further evidence of the effect of and risk of specific
cancers. Serotyping analyses showed that the development of
Kaposi's sarcoma in patients with full-blown AIDS was strongly
associated with HLA-DR5 (Pollack and Livingstone, 1985;
Smeraldi et al, 1986; Birkeland et al, 1995).
An MHC class II allele, DQBI*0301, has been shown to be
significantly linked to the incidence of melanoma and advanced
disease status (Lee et al, 1994), indicative of the association of
cancer development with MHC class II genes. Our findings that
HLA-DRBI*0101 and *0405 are protective alleles in patients with
renal cell carcinoma (Ozdemir et al, 1997) is well established, with
spontaneous regression of the RCC in some patients. The associa-
tion ofcervical carcinoma and MHC class II genes is still a matter
ofdispute, mainly owing to typing difficulties as stated (Glew et al,
1992). In addition, because a greater number ofclass II genes have
been detected by genomic analysis than by serology, new stan-
dards for bone marrow and other organ transplants have been
established (Tiercy et al, 1991; Ichikawa et al, 1993).
In conclusion, genotyping of MHC class II genes promises to
provide useful information for early tumour detection and for
predicting the prognosis ofpatients with various malignancies.
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